Indivior, the maker of an anti-addiction drug, has agreed to pay $600 million to settle criminal and civil investigations and plead guilty to a felony as part of the DOJ’s largest resolution involving opioids. The drugmaker pleaded guilty to making false statements relating to healthcare matters, as it sought to promote Suboxone Film, claiming it was safer than other drugs containing the same active ingredient, buprenorphine. Indivior’s former parent company previously paid $1.4 billion to resolve marketing claims related to Suboxone, which is used by patients suffering from opioid use disorder to reduce withdrawal symptoms.